Michael J. Theodorakis

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Assessing 10-Year Cardiovascular Disease Risk in Malaysians With Type 2 Diabetes Mellitus: Framingham Cardiovascular Versus United Kingdom Prospective Diabetes Study Equations.

Assessing 10-Year Cardiovascular Disease Risk in Malaysians With Type 2 Diabetes Mellitus: Framingham Cardiovascular Versus United Kingdom Prospective Diabetes Study Equations.

Journal: Asia-Pacific journal of public health
Published: September 20, 2019

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.

Journal: European journal of heart failure
Published: December 05, 2017

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Journal: The lancet. Diabetes & endocrinology
Published: August 07, 2017

Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.

Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.

Journal: American heart journal
Published: June 25, 2017

Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.

Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.

Journal: Current pharmaceutical design
Published: December 13, 2016

Modeling the oral glucose tolerance test in normal and impaired glucose tolerant states: a population approach.

Modeling the oral glucose tolerance test in normal and impaired glucose tolerant states: a population approach.

Journal: Current medical research and opinion
Published: November 01, 2016

Comment on Færch et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes 2015;64:2513-2525.

Comment on Færch et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes 2015;64:2513-2525.

Journal: Diabetes
Published: August 22, 2015

Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice.

Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice.

Journal: Expert opinion on pharmacotherapy
Published: June 17, 2015

On the potential of acarbose to reduce cardiovascular disease.

On the potential of acarbose to reduce cardiovascular disease.

Journal: Cardiovascular diabetology
Published: February 24, 2014

Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus.

Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus.

Journal: Diabetes, obesity & metabolism
Published: October 04, 2013

Nutritional clinical studies in dermatology.

Nutritional clinical studies in dermatology.

Journal: Journal of drugs in dermatology : JDD
Published: October 03, 2013

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.

Journal: ClinicoEconomics and outcomes research : CEOR
Published: July 23, 2013
Showing 1-12 of 17

Last Updated: 09/26/2026